

In the Claims:

16. (Amended) The process according to claim 1, wherein the compound having an amino group is a chitosan tri- to deca-saccharide, a chitosan tri- to deca-saccharide having a reduced terminal reducing group, a galactosamine tri- to deca-saccharide, a galactosamine tri- to deca-saccharide having a reduced terminal reducing group, serum albumin, fibrinogen, galactosyl serum albumin, amylase, pepsin, IgG, Fab, Fab', thyroid-stimulating hormone, a growth hormone, prolamine, glutelin, Pyr-Lys-Arg-Pro-Ser-Gln-Arg-Ser-Lys-Tyr-Leu (SEQ ID NO:1), D-Phe-octreotide, polylysine, oxytocin, bradykinin, valinomycin, colistin, an α -amino acid, a β -amino acid, a γ -amino acid, aniline, 4-methylaniline, 4-octylaniline, ethylamine, n-propylamine, isopropylamine, n-butylamine, sec-butylamine, isobutylamine, tert-butylamine, n-octylamine, n-decylamine, (1-naphthylmethyl)amine, N-methylaniline, N-methyl-4-ethylaniline, N-methyl-4-octylaniline, diethylamine, N-ethyl-N-propylamine, ethylenediamine, dansylethylenediamine, dansylhexamethylenediamine, N-(1-naphthyl)ethylenediamine, 1-naphthalenesulfonylethylenediamine, hexamethylenediamine, or phenylenediamine.

REMARKS

Enclosed herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification. Also submitted herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a disk copy of the Substitute Sequence Listing. The disk copy of the Substitute Sequence Listing, file "2185-0577P.ST25.TXT", is identical to the paper copy, except that it lacks formatting.

No new matter is introduced by these amendments.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any